Beld M, Penning M, van Putten M, van den Hoek A, Lukashov V, McMorrow M, Goudsmit J
Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
J Clin Microbiol. 1998 Oct;36(10):3002-6. doi: 10.1128/JCM.36.10.3002-3006.1998.
In the present study, the RIBA HCV serotyping SIA was evaluated with a cohort of injecting drug users. Serotyping may be a rapid and cost-effective method of determining genotypes in cohort studies. In this study, hepatitis C virus (HCV) antibody-positive sera from a cohort of 331 chronically infected injecting drug users, of which 167 were coinfected with human immunodeficiency virus (HIV), were serotyped by the RIBA HCV Serotyping SIA. Among the 331 specimens, serotype-specific antibodies were detected in 250 (sensitivity, 75. 5%), in which serotype 1 was predominant (57.2%), followed by serotype 3 (26.8%). Among the 331 specimens, 164 were HIV negative, and serotype-specific antibodies were detected in 151 (sensitivity, 92.1%), in which serotype 1 was predominant (59.6%), followed by serotype 3 (33.8%). For a subset of 58 samples taken from 19 chronically infected HCV seroconverters with a mean follow-up of 5 years, serotypes were compared with genotypes, which were determined by a line probe assay (HCV LiPa) and by direct sequencing of the products obtained by nested PCR of the 5' untranslated region. Among the 58 samples with known genotypes, serotype-specific antibodies were detected in 38 (total sensitivity, 65.5%), with a specificity of 78.9%. Thirty of these serotypeable samples revealed a serotype that corresponded to the genotype in the 58 samples (total positive predictive value, 51.7%). Of the 58 samples, 23 were coinfected with HIV, and when these were excluded, the total sensitivity increased to 76.5%, with a total specificity of 80.8% and a total positive predictive value of 61.8%. The serotyping assay showed a high total sensitivity (96.3%) for samples positive by HCV RIBA, version 3.0, with four bands. We conclude that the sensitivity of the RIBA HCV serotyping SIA is limited by the immunocompetence of the HCV-infected host. In general, samples from HIV-negative individuals containing genotype 1a had higher sensitivity, specificity, and concordance in the serotyping assay compared with genotyping, whereas samples containing genotype 3a were found to be more cross-reactive and untypeable. Therefore, the prevalence of genotypes other than genotype 1 could be underestimated if they are determined by serotyping, and improvements in specificity are recommended.
在本研究中,对一组注射吸毒者进行了重组免疫印迹法丙型肝炎病毒(HCV)血清分型条带免疫分析(SIA)。血清分型可能是队列研究中确定基因型的一种快速且经济高效的方法。在本研究中,采用重组免疫印迹法丙型肝炎病毒血清分型SIA对331名慢性感染注射吸毒者队列中的HCV抗体阳性血清进行了血清分型,其中167人同时感染了人类免疫缺陷病毒(HIV)。在这331份标本中,250份检测到血清型特异性抗体(灵敏度为75.5%),其中1型为主(57.2%),其次是3型(26.8%)。在这331份标本中,164份HIV阴性,151份检测到血清型特异性抗体(灵敏度为92.1%),其中1型为主(59.6%),其次是3型(33.8%)。从19名慢性感染HCV血清转换者中选取58份样本,平均随访5年,将血清型与基因型进行比较,基因型通过线性探针分析(HCV LiPa)以及对5'非翻译区巢式PCR产物进行直接测序来确定。在58份已知基因型的样本中,38份检测到血清型特异性抗体(总灵敏度为65.5%),特异性为78.9%。这些可血清分型的样本中有30份血清型与58份样本中的基因型相符(总阳性预测值为51.7%)。在58份样本中,23份同时感染了HIV,排除这些样本后,总灵敏度提高到76.5%,总特异性为80.8%,总阳性预测值为61.8%。对于HCV重组免疫印迹法3.0版本检测为阳性且有四条带的样本,血清分型检测显示出较高的总灵敏度(96.3%)。我们得出结论,重组免疫印迹法丙型肝炎病毒血清分型SIA的灵敏度受HCV感染宿主免疫能力的限制。总体而言,与基因分型相比,来自HIV阴性个体且含有1a基因型的样本在血清分型检测中具有更高的灵敏度、特异性和一致性,而含有3a基因型的样本则更易出现交叉反应且无法分型。因此,如果通过血清分型来确定,1型以外的其他基因型的流行率可能被低估,建议提高特异性。